tablets Loratadin are shown for symptomatic treatment of a chronic idiopathic urticaria and allergic rhinitis.

Structure

Active ingredient: loratadine;

1 tablet supports a loratadin in terms of 100% substance (0.01 g) of 10 mg;

Excipients: potato starch, lactoses monohydrate, povidone, calcium stearate.

Contraindication

Drug is contraindicated to patients with hypersensitivity to active ingredient or to any other component of drug.

Route of administration

Orally. Tablets can be applied irrespective of meal.

it is necessary to accept on 1 tablet (10 mg of a loratadin) of 1 times a day.

For children from 2 to 12 years the dosage depends on body weight. At body weight more than 30 kg: 10 mg (1 tablet) of 1 times a day. To children with body weight to apply less than 30 kg loratadin in the form of syrup.

Feature of use

Pregnant

Data on use of a loratadin. Researches on animals did not reveal straight lines or indirect negative effects concerning reproductive toxicity. It is desirable to avoid, as a security measure, use of the medicament Loratadin during pregnancy.

Efficiency and safety of use of a loratadin is not established to children up to 2 years by

. The medicament Loratadin, tablets to appoint to children with body weight more than 30 kg.

Drivers

generally medicament does not influence or influences slightly speed of response at control of motor transport or work with other mechanisms.

Nevertheless the patient needs to be informed that was very seldom reported about drowsiness cases which can affect ability to run motor transport or work with other mechanisms.

Overdose

Overdose of a loratadin increases the frequency of emergence of anticholinergic symptoms. At overdose it was reported about drowsiness, tachycardia and a headache. At overdose the symptomatic and supporting treatment during the necessary span is recommended. Use of activated carbon in the form of water suspension is possible. It is also possible to carry out gastric lavage. Loratadin is not brought from an organism when carrying out a hemodialysis; the efficiency of peritoneal dialysis in removal of medicament is unknown. After emergency aid the patient has to remain under medical observation.

Side effects

In clinical trials with participation of adults and teenagers at use of a loratadin in the recommended dose of 10 mg a day at the indications including allergic rhinitis and a chronic idiopathic small tortoiseshell about side reactions it was reported at 2% of patients (that exceeds an indicator at patients who received placebo). Side reactions about which it was reported more often than at placebo use were: drowsiness (1.2%), headache (0.6%), strengthening of appetite (0.5%) and insomnia (0.1%). In clinical trials at children from 2 to 12 years such undesirable phenomena as a headache (2.7%), nervousness (2.3%) or fatigue (1%) were noted.

Interaction

At use along with alcohol the effects of a loratadin amplify that is confirmed with researches of psychomotor function.

Potential interaction can take place at use of all known CYP3A4 or CYP2D6 inhibitors that leads to increase in levels of a loratadin, and it in turn can be the cause of increase in frequency of emergence of side reactions.

It was reported about increase in concentration of a loratadin in blood plasma after simultaneous use with ketokonazoly, erythromycin and Cimetidinum that was not followed by clinically significant changes (including on the ECG).

to Store

in original packing at a temperature not above 25 °C.

to Store

out of children's reach.

Expiration date - 4 years.